Business / Finance

RSS

MiMedx Group Q2 revenue increases more than 175%

MiMedx Group, Inc., an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today its results for the quarter ended June 30, 2013.

31 Jul 2013

Triple-S Management reports consolidated revenues of $599.8 million for Q2 2013

Triple-S Management Corporation, the leading managed care company in Puerto Rico, today announced consolidated revenues of $599.8 million and consolidated operating income of $16.8 million for the three months ended June 30, 2013.

31 Jul 2013

Blackbaud announces total revenue increase of 14% for Q2 2013

Blackbaud, Inc., a leading global provider of software and services for nonprofits, today announced financial results for its second quarter ended June 30, 2013.

31 Jul 2013

Naurex receives new U.S. patent for its lead compound, GLYX-13

Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced issuance of a new U.S. patent for its lead compound, GLYX-13.

31 Jul 2013

Hamamatsu places $500,000 order for Zecotek’s LFS scintillation crystals

Zecotek Photonics Inc., a developer of leading-edge photonics technologies for medical, industrial and scientific markets, today announced that it has received a $500,000 order for its patented Lutetium Fine Silicate (LFS) scintillation crystals from its strategic partner Hamamatsu Photonics (Tokyo: 6965) of Japan.

31 Jul 2013

Baxter, JW Holdings sign distribution, license agreement for omega 3 parenteral nutrition products

Baxter International Inc. and JW Holdings today announced that they have entered into an exclusive distribution and license agreement for parenteral nutritional products containing a novel formulation of omega 3 lipids.

From Baxter International Inc. 31 Jul 2013

AstraZeneca, FibroGen partner to develop, commercialize anemia drug candidate FG-4592

AstraZeneca and FibroGen today announced that they have entered into a strategic collaboration to develop and commercialize FG-4592, a first-in-class oral compound in late stage development for the treatment of anemia associated with chronic kidney disease and end-stage renal disease.

31 Jul 2013

Community Health Systems, Health Management Associates enter into definitive merger agreement

Community Health Systems, Inc. and Health Management Associates, Inc. announced today that they have entered into a definitive merger agreement pursuant to which CHS will acquire HMA for approximately $7.6 billion, including the assumption of approximately $3.7 billion of indebtedness.

30 Jul 2013

Adocia, Lilly terminate collaboration agreement relating to fast-acting insulin analog

Adocia, a biotechnology company specializing in the development of ‘best-in-class’ medicines from already approved therapeutic proteins, announced today that it had agreed with Eli Lilly and Company not to continue further joint research under the licensing agreement signed in December 2011 relating to use of Adocia's BioChaperone(R) technology for the formulation of fast acting insulin analog formulated with the BioChaperone(R) technology. Consequently, the two companies have terminated the collaboration.

30 Jul 2013

National health and social care charity, Community Integrated Care, launches new five year strategy

National health and social care charity Community Integrated Care is proud to announce the launch of its new five year strategy, in which the organisation has committed to becoming ‘The UK’s Leading Health and Social Care Charity’.

From Community Integrated Care 29 Jul 2013

FDA grants orphan-drug designation for Ligand’s Captisol-enabled Topiramate Injection

Ligand Pharmaceuticals Incorporated announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation for its proprietary Captisol-enabled Topiramate Injection for the treatment of partial onset or primary generalized tonic-clonic seizures in hospitalized epilepsy patients who are unable to take oral topiramate.

26 Jul 2013

Columbia Laboratories’ Board of Directors set a ratio of 1-for-8 for its reverse stock split

Columbia Laboratories, Inc. ("Columbia" or the "Company") (NasdaqCM: CBRX) announced today that its Board of Directors (the "Board") has set a ratio of 1-for-8 for its previously approved reverse stock split of its common stock, and an anticipated effective date for the reverse stock split of the later of (i) the filing with the Secretary of the State of Delaware of a certificate of amendment with respect to the reverse stock split or (ii) August 9, 2013.

26 Jul 2013

Piramal's Healthcare invests USD 2.5 million to upgrade ADC manufacturing suites

Piramal's Healthcare vertical today announced that it is to invest USD 2.5 million at its FDA approved Grangemouth, UK, site to upgrade one of its antibody drug conjugate (ADC) manufacturing suites, from clinical phase to commercial grade, in response to customer demand.

26 Jul 2013

Zydus, IDRI partner to develop visceral leishmaniasis vaccine candidate

In a unique partnership, Zydus, India's fourth largest healthcare group and an innovation-led global healthcare provider, and IDRI, a Seattle-based non-profit research and product development organization, announced today they are collaborating on the production and clinical development of IDRI's visceral leishmaniasis vaccine candidate, designed to prevent the deadly parasitic disease.

26 Jul 2013

Ascendancy Healthcare signs multi-year collaboration with Quintiles

Ascendancy Healthcare, Inc. dedicated to the commercialization of therapeutic products to meet unmet medical needs in China and other high-growth Asian markets, announced today a multi-year collaboration with Quintiles, the world's largest provider of biopharmaceutical development and commercial outsourcing services.

25 Jul 2013

Mylan, Orion sign settlement, license agreement for generic version of STALEVO

Mylan Inc. today confirmed that Mylan Pharmaceuticals Inc. and Orion Corporation have entered into a settlement and license agreement settling the parties litigation in connection with Mylan's filing of an Abbreviated New Drug Application with the U.S. Food and Drug Administration for Carbidopa/Levodopa/Entacapone Tablets, 12.5 mg/50 mg/200 mg, 18.75 mg/75 mg/200 mg, 25 mg/100 mg/200 mg, 31.25 mg/125 mg/200 mg, 37.5 mg/150 mg/200 mg, and 50 mg/200 mg/200 mg.

25 Jul 2013

NeuroMetrix announces business and financial highlights for second quarter

NeuroMetrix, Inc. (the "Company"), a medical device company focused on the treatment of the neurological complications of diabetes, today reported business and financial highlights for the second quarter ended June 30, 2013.

25 Jul 2013

Magellan Health Services announces financial results for second quarter 2013

Magellan Health Services Inc. today reported financial results for the second quarter 2013, as summarized below. For the quarter ended June 30, 2013, the company reported net revenue of $842.7 million, segment profit of $75.0 million, and net income of $31.5 million or $1.15 per diluted common share.

25 Jul 2013

Colgate reports worldwide Net sales of $4,346 million in second quarter 2013

Colgate-Palmolive Company today reported worldwide Net sales of $4,346 million in second quarter 2013, an increase of 2.0% versus second quarter 2012. Global unit volume grew 4.0%, pricing increased 1.0% and foreign exchange was negative 3.0%. Organic sales (Net sales excluding foreign exchange, acquisitions and divestments) grew 5.5%.

25 Jul 2013

NxStage Medical revenue increases 11% to $65.5 million in Q2 2013

NxStage Medical, Inc., a leading manufacturer of innovative dialysis products, today reported second quarter financial results with total revenue at the top end of its guidance range.

25 Jul 2013

Business / Finance

MiMedx Group Q2 revenue increases more than 175%

Triple-S Management reports consolidated revenues of $599.8 million for Q2 2013

Blackbaud announces total revenue increase of 14% for Q2 2013

Naurex receives new U.S. patent for its lead compound, GLYX-13

Hamamatsu places $500,000 order for Zecotek’s LFS scintillation crystals

Baxter, JW Holdings sign distribution, license agreement for omega 3 parenteral nutrition products

AstraZeneca, FibroGen partner to develop, commercialize anemia drug candidate FG-4592

Community Health Systems, Health Management Associates enter into definitive merger agreement

Adocia, Lilly terminate collaboration agreement relating to fast-acting insulin analog

National health and social care charity, Community Integrated Care, launches new five year strategy

FDA grants orphan-drug designation for Ligand’s Captisol-enabled Topiramate Injection

Columbia Laboratories’ Board of Directors set a ratio of 1-for-8 for its reverse stock split

Piramal's Healthcare invests USD 2.5 million to upgrade ADC manufacturing suites

Zydus, IDRI partner to develop visceral leishmaniasis vaccine candidate

Ascendancy Healthcare signs multi-year collaboration with Quintiles

Mylan, Orion sign settlement, license agreement for generic version of STALEVO

NeuroMetrix announces business and financial highlights for second quarter

Magellan Health Services announces financial results for second quarter 2013

Colgate reports worldwide Net sales of $4,346 million in second quarter 2013

NxStage Medical revenue increases 11% to $65.5 million in Q2 2013

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Latest News